[go: up one dir, main page]

WO2012130720A3 - PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS - Google Patents

PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS Download PDF

Info

Publication number
WO2012130720A3
WO2012130720A3 PCT/EP2012/055097 EP2012055097W WO2012130720A3 WO 2012130720 A3 WO2012130720 A3 WO 2012130720A3 EP 2012055097 W EP2012055097 W EP 2012055097W WO 2012130720 A3 WO2012130720 A3 WO 2012130720A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
treatment
responsiveness
pi3k
pik3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/055097
Other languages
French (fr)
Other versions
WO2012130720A2 (en
Inventor
Sebastian NIJMAN
Markus MUELLNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CEMM Forschungszentrum fuer Molekulare Medizin GmbH
Original Assignee
CEMM Forschungszentrum fuer Molekulare Medizin GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CEMM Forschungszentrum fuer Molekulare Medizin GmbH filed Critical CEMM Forschungszentrum fuer Molekulare Medizin GmbH
Publication of WO2012130720A2 publication Critical patent/WO2012130720A2/en
Publication of WO2012130720A3 publication Critical patent/WO2012130720A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for determining the responsiveness of a mammalian tumor cell to treatment with an inhibitor of the phosphoinosite 3-kinase (PI3K) and/or mammalian target of rapamycin (mTOR) pathway, said method comprising determining the c-MYC and/or NOTCH1 level in said tumor cell, wherein said level is indicative of whether the cell is likely to respond or is responsive to the treatment. It further refers to an in vitro method for the identification of a resistance to treatment or of predicting or monitoring the efficacy of treatment, of solid tumor cancer with an inhibitor of the PI3K and/or mTOR pathway in a patient suffering from said cancer. It further refers to a combination comprising an amount of an inhibitor of the PI3K and/or mTOR pathway, and an amount of a c-MYC and/or NOTCH 1 inhibitor.
PCT/EP2012/055097 2011-03-28 2012-03-22 PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS Ceased WO2012130720A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161468418P 2011-03-28 2011-03-28
EP11160039.1 2011-03-28
EP11160039 2011-03-28
US61/468,418 2011-03-28

Publications (2)

Publication Number Publication Date
WO2012130720A2 WO2012130720A2 (en) 2012-10-04
WO2012130720A3 true WO2012130720A3 (en) 2012-12-20

Family

ID=44343936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/055097 Ceased WO2012130720A2 (en) 2011-03-28 2012-03-22 PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS

Country Status (1)

Country Link
WO (1) WO2012130720A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138585A1 (en) 2012-03-16 2013-09-19 The Broad Institute, Inc. Multiplex methods to assay mixed cell populations simultaneously
EP3105353A4 (en) 2014-02-12 2017-11-01 Dana-Farber Cancer Institute, Inc. P13k-mtorc1-s6k1 signaling pathway biomarkers predictive of anti-cancer responses
EP3833784A1 (en) * 2018-08-07 2021-06-16 PIQUR Therapeutics AG Treatment of squamous cell carcinoma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122053A2 (en) * 2005-05-09 2006-11-16 Ariad Gene Therapeutics, Inc. Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor
WO2009039457A1 (en) * 2007-09-19 2009-03-26 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
WO2009103790A2 (en) * 2008-02-21 2009-08-27 Universite Libre De Bruxelles Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications
WO2010030865A2 (en) * 2008-09-11 2010-03-18 The Regents Of The University Of California Loss of fbxw7 is a biomarker of sensitivity to treatment of tumors with inhibitors of mtor
WO2010040124A1 (en) * 2008-10-03 2010-04-08 Dana-Farber Cancer Institute, Inc. Compositions, kits and methods for the diagnosis, prognosis, and monitoring of cancer using golph3

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122053A2 (en) * 2005-05-09 2006-11-16 Ariad Gene Therapeutics, Inc. Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor
WO2009039457A1 (en) * 2007-09-19 2009-03-26 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
WO2009103790A2 (en) * 2008-02-21 2009-08-27 Universite Libre De Bruxelles Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications
WO2010030865A2 (en) * 2008-09-11 2010-03-18 The Regents Of The University Of California Loss of fbxw7 is a biomarker of sensitivity to treatment of tumors with inhibitors of mtor
WO2010040124A1 (en) * 2008-10-03 2010-04-08 Dana-Farber Cancer Institute, Inc. Compositions, kits and methods for the diagnosis, prognosis, and monitoring of cancer using golph3

Also Published As

Publication number Publication date
WO2012130720A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
WO2008127718A3 (en) Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2011135459A3 (en) Methods and devices for predicting treatment efficacy
WO2009045389A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2013083098A3 (en) Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors
NZ608459A (en) Molecular diagnostic test for cancer
WO2010048123A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2008115419A3 (en) Gene expression markers for prediction of patient response to chemotherapy
HK1219421A1 (en) Combination of kinase inhibitors and uses thereof
NZ600268A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2006101925A3 (en) Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2012012693A3 (en) Methods for detecting signatures of disease or conditions in bodily fluids
WO2013093635A3 (en) Plasma micrornas for the detection of early colorectal cancer
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
EA201390149A1 (en) METHODS FOR DETECTING DISEASES OR PATHOLOGICAL CONDITIONS USING PHAGOCYTARY CELLS
WO2011109584A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011133477A3 (en) Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
NZ597655A (en) Method for predicting efficacy of drugs in a patient
WO2013080050A3 (en) Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
WO2009045361A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011047033A3 (en) Biomarker for identification of melanoma tumor cells
EA201590024A1 (en) METHODS FOR IDENTIFYING DISEASES OR CONDITIONS WITH THE APPLICATION OF CIRCULATING PATIOUS CELLS
WO2011146945A3 (en) Alk and ros kinase in cancer
WO2012079059A3 (en) Post-treatment breast cancer prognosis
WO2013071163A3 (en) Biomarkers of response to proteasome inhibitors
WO2011127202A3 (en) Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12724578

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12724578

Country of ref document: EP

Kind code of ref document: A2